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Arterial or venous thrombotic events have been described as complications in patients with positive anticardiolipin anti-
bodies (aCL), affecting various organs including the heart. In order to see whether aCL could be, among others, a
predisposing factor for coronary artery occlusions and whether it could serve as a prognostic marker for coronary heart
disease, 232patients enrolled in the European Concerted Action on Thrombosis Angina Pectoris Study were studied. aCL
and various other haemostatic parameters were determined at time of admittance in order to see whether a relationship
existed between haemostasis at baseline and extent or prognosis of the cardiovascular disease. A follow-up at 12 and 24
months after angiography included information about relapsing coronary or other thrombotic events, treatment and
outcome of the disease. aCL were not found to be a marker of either progressive cardiovascular disease or recurrent
thrombotic events. No correlation was found, either in aCL positive or in aCL negative patients, between high levels
of haemostasis activation markers, such as fi-thromboglobulin, platelet factor 4 or fibrinopeptide A and recurrent
cardiovascular disease.
Introduction
Lupus anticoagulants and/or anticardiolipin antibodies
(aCL) interfere with haemostasis and result in a higher
predisposition for thrombosis1'-21. These antibodies
were primarily described in patients with systemic lupus
erythematosus but they also occur in many other auto-
immune disorders'31. Arterial or venous thrombotic events
have been described as complications in such disorders
affecting various organs including the heart, for which
episodes of thrombotic endocarditis or coronary artery
occlusions have been described14-61. The aim of this study
was to see whether aCL could be, among others, a predis-
posing factor for coronary artery occlusions and whether
they could serve as a prognostic marker for coronary
heart disease (CHD).
Patients and methods
PATIENT RECRUITMENT
Over a period of 2 years we studied 232 patients (198
men aged 55 ±9 years and 34 women aged 56 ± 10 years)
with angina pectoris admitted during remission to the
Cardiology Department, as outpatients for evaluation of
their cardiovascular disease. All underwent coronary
angiography. Since they were enrolled in the European
Concerted Action on Thrombosis Angina Pectoris Study
(ECAT), various haemostatic parameters were also deter-
mined at the time of admittance in order to see whether a
relationship existed between haemostasis at baseline and
extent or prognosis of the cardiovascular disease.
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PATIENT HISTORY
Medical history was focused on previous myocardial
infarction and/or other thrombotic events as well as cur-
rent treatment. Chest pain was classified in four categories,
namely resting angina, effort angina, other chest pain and
no chest pain.
CORONARY ANGIOGRAPHY
Angiography was carried out following the Judkins
technique scoring the left main, the left anterior descend-
ing, the circumflex and the right coronary artery in three
categories: (a) stenosis less than 50% in diameter reduc-
tion, (b) stenosis between 50% and less than 100% and (c)
total occlusion 100%. In addition, the ejection fraction
(EF, %) and the left ventricular end diastolic pressure
(LVEDP, mmHg) were determined.
LABORATORY EXAMINATIONS
From the general laboratory tests haematocrit,
leukocyte count, platelet count, triglycerides and total
cholesterol were measured according to classical methods.
Haemostasis screening included activated partial
thromboplastin time (APTT), /?-thromboglobulin (fi-TG),
platelet factor 4 (PF4), von Willebrand factor antigen
(vWF:Ag), factor VIII activity (VIII:C), fibrinopeptide A
(FPA), fibrinogen (Fbg) and euglobulin lysis time (ELT)
before and after a lOmin venous stasis. All were deter-
mined according to known methods standardized by the
steering committee for quality control of the ECAT
study™.
Anticardiolipin IgG, IgM and IgA antibodies were
measured with a commercial kit (QUANTA Lite ACA by
Inova Diagnostics Inc, U.S.A.). The method uses an
enzyme-linked immunoassay based on the one described
by Harris el al., giving the results in arbitrary GPL, MPL
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Table I Means and standard deviations of various laboratory parameters in 232 patients
Age (years)
Weight (kg)
Ejection fraction (%)
LVEDP (mmHg)
Haematocrit (%)
Leukocytes (x 10M"')
Platelets(x 10'. I 1 )
Triglycerides (mmol. 1 -')
Cholesterol total (mmol. I"1)
APTT(s)
/Mhromboglobulm (ng .ml"1)
Platelet factor 4 (ng .ml"1)
VIII:C(%)
vWF:Ag (%)
Fibrinopeptide A (ng. ml ')
Fibnnogen(g. 1"')
3ELT (% reduction)
aCL pos
(n = 35)
55-3±9-0
79 2± 11-9
63-2± 12-2
17-4±8-2
42-9±81
6-4 ±1-6
245-7±74-5
2-4 ±1-6
6-7 ± 1 0
59-4 ±29-8
47-6±27-9
8-6 ± 9 0
145-1-43
140±47
5-0±I0-4
2-41 ±0-49
43-6±34-8
aCL neg
(n=197)
550±8-7
75-8 ±111
63-9± 12-6
17 7±6-8
43-2±3-6
6-9 ±40
2501 ±60 5
2 7± 1-9
6-5 ± 1 - 2
5 1 - 3 ± 16-8
45-6±251
8-9 ± 1 7 0
135±41
138±52
4-5± 14-3
2-43 ±0-52
34-5 ±31-6
Normal
values
—
>55
<15
37-53
30-9-6
143-400
0-5-2-7
3-7-70
38-45
<52
< 10-4
49-226
49-226
<2-0
1-7-4-1
M W
IVl- W
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
aCL = anticardiolipin antibodies; M-W = Mann-Whitney non-parametnc test; LVEDP = left ven-
tricular end-diastolic pressure; APTT = activated partial thromboplastin time; VIII:C = factor VIII
activity; vWF:Ag = von Willebrand factor antigen; 3ELT = percent reduction of euglobulin lysis time
before and after venous occlusion.
Table 2 Prevalence ofaCL in patients with abnormal or normal fi-thromboglobulin, (^-TG), platelet factor 4 (PF4) orfibrinopeptide A (FPA)
given as absolute numbers of patients for each category. In brackets the percentage of aC L-positive patients in each subgroup
aCL pos
aCL neg
chi-square test
0-TG
(>52ng.ml
9(17 6%)
42
j
P-TG
') (<52ng.ml ')
26(14-4%)
155
" = 0-56
PF4
(>10-4ng.ml ')
9(19-2%)
38
P=
PF4
($10-4ng.ml ')
26(14-2%)
157
0-40
FPA
( > 2 n g . ml '
17(15-9%)
90
1
FPA
18(14-8%)
104
D
 = 0-80
and APL units, on the basis of predefined standards'2-81.
Since the ECAT probes contained citrated plasma which
had been centrifuged and stored for a long period, more
than 3 years at — 70 °C, the normal range for aCL was
defined separately in plasma taken from 85 healthy blood
donors, handled and stored under the same conditions as
the samples of the ECAT patients. The mean plus four
standard deviations were taken as cut-off points, which
were far beyond the 95th percentiles, in the knowledge
that this distribution is not normal (IgG-aCL < 3-6 GPL,
IgM-aCL <30MPL, IgA-aCL < 5-2 APL).
FOLLOW-UP
Patients were followed-up for one and 2 years after
initial angiography. Information gathered was concen-
trated on new myocardial infarctions, other major vascu-
lar events and further disease treatment. Except for six
patients who did not survive the first year and three
patients the second, follow-up was complete.
STATISTICS
For statistical evaluation, the chi-square test and the
non-parametric Mann-Whitney U-test were used as
indicated in the results.
Results
A total of 35 out of 232 evaluated patients (15-1 %) were
found to have positive aCL, 12 with IgG, 20 with IgM,
three with IgA and two with both IgG/IgA. Comparing
the two groups, aCL positive and aCL negative, for the
various laboratory parameters (non-parametric Mann-
Whitney test) no statistically significant differences were
found (Table 1). The prevalence of past myocardial
infarction was almost the same in aCL-positive and nega-
tive groups (48% and 38% respectively, chi-square P =
0-32), which makes the groups comparable with respect to
recurrent myocardial infarctions.
Patients with previous myocardial infarction (39-5% of
total) showed a higher prevalence of aCL than others
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Table 3 Frequency of cardiovascular episodes during the two years after angiography in patients grouped according to normal or abnormal
P-thromboglobulin (fi-TG), platelet factor 4 (PF4) or fibrinopeplide A (FPA) levels given as percent of affected patients for each subgroup
/J-TG
(>52ng.ml-') (sS52ng. ml"1)
PF4
10-4ng.ml-')
PF4 FPA
(>2ng.m]-')
FPA
aCLpos
aCL ncg
0%
14-3%
19-2%
11-6%
0%
13-2%
19-2%
11-5%
5-9%
7-8%
22-2%
16-3%
(aCL positivity, 18-5% and 13-3% respectively), the dif-
ference was not statistically significant (chi-square test,
P = 0-29). New myocardial infarctions and/or other vas-
cular thrombotic events were recorded during the 2-year
follow-up period. Overall, 14-3% of aCL positives and
12-2% of aCL negatives suffered from recurrent episodes
(chi-square test, P=0-73). Oral anticoagulation had no
effect on recurrencies in aCL-positive and aCL-negative
patients.
The influence of positive aCL upon severity of chest
pain was tested by comparing the rate of positivity in all
patients after having classified them in four groups
according to the type of chest pain. Thus 19-6% had rest-
ing angina, 64% effort angina, 8-9% other chest pain and
7-5% no pain. No statistically significant difference was
found between aCL positivity rates in the four groups
(18-2%, 11-8%, 20% and 29-4% respectively, chi-square
test P = 0-2). Similarly, according to severity of occlusion
no statistically significantly different aCL positivity rates
were found in the three groups classified as described
under Methods (11-7%, 16-7% and 11-6% respectively,
chi-square test P = Q19).
In Table 2, patients were grouped according to their y?-
TG, PF4 or FPA levels. No statistically significant differ-
ence in the prevalence of positive aCL was found between
those with abnormal and normal values of the above
mentioned parameters. Table 3 shows the frequency of
recurrent myocardial infarctions or other vascular epi-
sodes in the same subgroups during 2 years following
angiography. No statistically significant differences were
found between those with abnormal and normal
activation markers.
Discussion
Since the description of aCL in the early 1980s and the
observed association with thrombotic disease, various
patient groups whose main disease was a thrombotic
event have been studied, including those with coronary
heart disease19""1. Hamsten et al.m found a prevalence of
positive aCL in 21% of young survivors of myocardial
infarction. The majority of these aCL-positive patients
subsequently suffered a second cardiovascular event,
leading the authors to suggest that aCL could be used as a
marker for high risk of recurrence of cardiovascular
events. Another observation by Eber et a/.'101, on 74
unselected males, did not show such a correlation and
concluded that aCL are not high-risk markers. Various
other groups reported that aCL could accelerate progress
of cardiovascular disease or appearance of thrombotic
complications'6"1.
In our study on patients with documented coronary
heart disease, the prevalence of positive aCL (151%) is
similar to that described by others'121. Only three of the 35
positives had IgA-aCL alone, which diminishes the value
of determination of the IgA-class of antibodies. As
shown, the presence of aCL was not accompanied by any
statistically significant rise in indicators of haemostasis
activation, such as /?-TG, PF4, FPA. The relative risk
(ratio of the cumulative incidences in the aCL-positive
and negative groups) for suffering a second myocardial
infarction or other vascular event in patients with positive
aCL was 117. Taking only the patients treated with anti-
platelet drugs or oral anticoagulants this risk hardly dif-
fered at all (1-40). Moreover, in those with abnormally
high y?-TG, PF4 or FPA we found neither a higher
prevalence of aCL nor a higher frequency of recurrent
cardiovascular episodes (Table 3). This means that these
haemostasis activation markers could not be considered
predictive of recurrencies and that no direct relationship
between recurrencies and aCL could be postulated. Those
with a previous myocardial infarction showed higher aCL
rates compared to those without, which is in accordance
with other observations1"1. However, among the aCL-
positive group, those with a previous myocardial infarc-
tion did not show a statistically significantly higher
frequency of new cardiovascular events than those with-
out a previous myocardial infarction (17-6% vs 111%,
chi-square test /> = 0-58). Moreover, in the group with an
old myocardial infarction, those with positive aCL did
not present statistically significantly higher rates of new
cardiovascular events than those with negative aCL
(17-6% vs 9-3%, chi-square test P = 0-32). It could be that
positive aCL also appear after myocardial infarction,
pathogenetically linked to cell damage caused by myocar-
dial ischaemia, as it has already been hypothesized by
others'"1. They did not, however, have a predictive value
concerning recurrent cardiovascular events, as shown by
our results. aCL positives did not, on the other hand,
differ from negatives with respect to the severity of chest
pain or coronary stenosis, showing no correlation with
the pathogenesis of CHD.
In conclusion, aCL in patients with coronary heart dis-
ease were not found to be markers of either progressive
cardiovascular disease or recurrent thrombotic events.
No relationship could be found between recurrent cardio-
vascular disease and fi-TG, PF4 or FPA in aCL positive or
aCL negative patients.
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